ARVINAS, INC. Payments to Acquire Marketable Securities
ARVINAS, INC. (ARVN) reported Payments to Acquire Marketable Securities of $239.30 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2026-08-04
- ARVINAS, INC. payments to acquire marketable securities for the quarter ending 2026-06-30 was $60.40M, a 48.81% decline year-over-year.
- ARVINAS, INC. payments to acquire marketable securities for the quarter ending 2026-03-31 was $178.90M, a 49.58% increase year-over-year.
- ARVINAS, INC. payments to acquire marketable securities for the quarter ending 2025-12-31 was $6.60M, a 87.13% decline year-over-year.
- ARVINAS, INC. payments to acquire marketable securities for the quarter ending 2025-09-30 was $110.00M, a 31.42% decline year-over-year.
- ARVINAS, INC. payments to acquire marketable securities for fiscal 2025 was $354.20M, a 45.68% decline from fiscal 2024.
- ARVINAS, INC. payments to acquire marketable securities for fiscal 2024 was $652.10M, a 31.81% decline from fiscal 2023.
- ARVINAS, INC. payments to acquire marketable securities for fiscal 2023 was $956.30M, a 7.89% increase from fiscal 2022.
- ARVINAS, INC. payments to acquire marketable securities for fiscal 2022 was $886.40M, a 49.19% decline from fiscal 2021.
| Period end | Payments to Acquire Marketable Securities 3 month | Payments to Acquire Marketable Securities 3 month as first filed | Payments to Acquire Marketable Securities 6 month | Payments to Acquire Marketable Securities 6 month as first filed | Payments to Acquire Marketable Securities 9 month | Payments to Acquire Marketable Securities 9 month as first filed | Payments to Acquire Marketable Securities 12 month | Payments to Acquire Marketable Securities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $60.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $239.30M 10-Q · filed 2026-08-04 | $245.90M derived: sum of 3 quarters · filed 2026-08-04 | $355.90M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2026-03-31 | $178.90M 10-Q · filed 2026-05-11 | $185.50M derived: sum of 2 quarters · filed 2026-05-11 | $295.50M derived: sum of 3 quarters · filed 2026-05-11 | $413.50M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-12-31 | $6.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $116.60M derived: sum of 2 quarters · filed 2026-02-24 | $234.60M derived: sum of 3 quarters · filed 2026-08-04 | $354.20M 10-K · filed 2026-02-24 | ||||
| 2025-09-30 | $110.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $228.00M derived: sum of 2 quarters · filed 2026-08-04 | $347.60M 10-Q · filed 2025-11-05 | $398.90M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-06-30 | $118.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $237.60M 10-Q · filed 2026-08-04 | $288.90M derived: sum of 3 quarters · filed 2026-08-04 | $449.30M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-03-31 | $119.60M 10-Q · filed 2026-05-11 | $170.90M derived: sum of 2 quarters · filed 2026-05-11 | $331.30M derived: sum of 3 quarters · filed 2026-05-11 | $523.80M derived: sum of 4 quarters · filed 2026-05-11 | ||||
| 2024-12-31 | $51.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $211.70M derived: sum of 2 quarters · filed 2026-02-24 | $404.20M derived: sum of 3 quarters · filed 2026-02-24 | $652.10M 10-K · filed 2026-02-24 | ||||
| 2024-09-30 | $160.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $352.90M derived: sum of 2 quarters · filed 2025-11-05 | $600.80M 10-Q · filed 2025-11-05 | $891.40M derived: sum of 4 quarters · filed 2026-02-24 | ||||
| 2024-06-30 | $192.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $440.40M 10-Q · filed 2025-08-06 | $731.00M derived: sum of 3 quarters · filed 2026-02-24 | $904.40M derived: sum of 4 quarters · filed 2026-02-24 | ||||
| 2024-03-31 | $247.90M 10-Q · filed 2025-05-01 | $538.50M derived: sum of 2 quarters · filed 2026-02-24 | $711.90M derived: sum of 3 quarters · filed 2026-02-24 | $1.03B derived: sum of 4 quarters · filed 2026-02-24 | ||||
| 2023-12-31 | $290.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $464.00M derived: sum of 2 quarters · filed 2026-02-24 | $780.60M derived: sum of 3 quarters · filed 2026-02-24 | $956.30M 10-K · filed 2026-02-24 | ||||
| 2023-09-30 | $173.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-30 | $490.00M derived: sum of 2 quarters · filed 2024-10-30 | $665.70M 10-Q · filed 2024-10-30 | $849.90M derived: sum of 4 quarters · filed 2025-02-11 | ||||
| 2023-06-30 | $316.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-30 | $492.30M 10-Q · filed 2024-07-30 | $676.50M derived: sum of 3 quarters · filed 2025-02-11 | $909.60M derived: sum of 4 quarters · filed 2025-02-11 | ||||
| 2023-03-31 | $175.70M 10-Q · filed 2024-05-07 | $359.90M derived: sum of 2 quarters · filed 2025-02-11 | $593.00M derived: sum of 3 quarters · filed 2025-02-11 | $798.90M derived: sum of 4 quarters · filed 2025-02-11 | ||||
| 2022-12-31 | $184.20M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-11 | $417.30M derived: sum of 2 quarters · filed 2025-02-11 | $623.20M derived: sum of 3 quarters · filed 2025-02-11 | $886.40M 10-K · filed 2025-02-11 | ||||
| 2022-09-30 | $233.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $439.00M derived: sum of 2 quarters · filed 2023-11-07 | $702.20M 10-Q · filed 2023-11-07 | $1.04B derived: sum of 4 quarters · filed 2024-02-27 | ||||
| 2022-06-30 | $205.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $469.10M 10-Q · filed 2023-08-08 | $810.80M derived: sum of 3 quarters · filed 2024-02-27 | $1.68B derived: sum of 4 quarters · filed 2024-02-27 | ||||
| 2022-03-31 | $263.20M 10-Q · filed 2023-05-05 | $604.90M derived: sum of 2 quarters · filed 2024-02-27 | $1.47B derived: sum of 3 quarters · filed 2024-02-27 | $1.77B derived: sum of 4 quarters · filed 2024-02-27 | ||||
| 2021-12-31 | $341.70M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $1.21B derived: sum of 2 quarters · filed 2024-02-27 | $1.50B derived: sum of 3 quarters · filed 2024-02-27 | $1.74B 10-K · filed 2024-02-27 | ||||
| 2021-09-30 | $864.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $1.16B derived: sum of 2 quarters · filed 2022-11-09 | $1.40B 10-Q · filed 2022-11-09 | $1.40B 10-Q · filed 2021-11-03 | $1.40B derived: sum of 4 quarters · filed 2023-02-23 | |||
| 2021-06-30 | $297.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $538.00M 10-Q · filed 2022-08-04 | $537.97M 10-Q · filed 2021-08-05 | $538.00M derived: sum of 3 quarters · filed 2023-02-23 | $538.00M derived: sum of 4 quarters · filed 2023-02-23 | |||
| 2021-03-31 | $240.50M 10-Q · filed 2022-05-05 | $240.50M 10-Q · filed 2021-05-04 | $240.50M derived: sum of 2 quarters · filed 2023-02-23 | $240.50M derived: sum of 3 quarters · filed 2023-02-23 | $273.09M derived: sum of 4 quarters · filed 2023-02-23 | |||
| 2020-12-31 | $3.83K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $3.83K derived: sum of 2 quarters · filed 2023-02-23 | $32.59M derived: sum of 3 quarters · filed 2023-02-23 | $41.20M 10-K · filed 2023-02-23 | $41.20M 10-K · filed 2021-03-01 | |||
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $32.59M derived: sum of 2 quarters · filed 2021-11-03 | $41.20M 10-Q · filed 2021-11-03 | $184.64M derived: sum of 4 quarters · filed 2022-02-28 | ||||
| 2020-06-30 | $32.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $41.20M 10-Q · filed 2021-08-05 | $184.64M derived: sum of 3 quarters · filed 2022-02-28 | $259.84M derived: sum of 4 quarters · filed 2022-02-28 | ||||
| 2020-03-31 | $8.61M 10-Q · filed 2021-05-04 | $152.05M derived: sum of 2 quarters · filed 2022-02-28 | $227.25M derived: sum of 3 quarters · filed 2022-02-28 | $261.84M derived: sum of 4 quarters · filed 2022-02-28 | ||||
| 2019-12-31 | $143.44M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $218.65M derived: sum of 2 quarters · filed 2022-02-28 | $253.24M derived: sum of 3 quarters · filed 2022-02-28 | $256.50M 10-K · filed 2022-02-28 | $256.55M 10-K · filed 2020-03-16 | |||
| 2019-09-30 | $75.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $109.79M derived: sum of 2 quarters · filed 2020-11-05 | $113.06M 10-Q · filed 2020-11-05 | $233.56M derived: sum of 4 quarters · filed 2021-03-01 | ||||
| 2019-06-30 | $34.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-04 | $37.85M 10-Q · filed 2020-08-04 | $158.35M derived: sum of 3 quarters · filed 2021-03-01 | $166.43M derived: sum of 4 quarters · filed 2021-03-01 | ||||
| 2019-03-31 | $3.26M 10-Q · filed 2020-04-28 | $123.76M derived: sum of 2 quarters · filed 2021-03-01 | $131.83M derived: sum of 3 quarters · filed 2021-03-01 | $191.10M derived: sum of 4 quarters · filed 2021-03-01 | ||||
| 2018-12-31 | $120.50M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $128.57M derived: sum of 2 quarters · filed 2021-03-01 | $187.84M derived: sum of 3 quarters · filed 2021-03-01 | $234.89M 10-K · filed 2021-03-01 | ||||
| 2018-09-30 | $8.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-04 | $67.34M derived: sum of 2 quarters · filed 2019-11-04 | $114.39M 10-Q · filed 2019-11-04 | $117.59M derived: sum of 4 quarters · filed 2019-11-04 | ||||
| 2018-06-30 | $59.27M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-05 | $106.32M 10-Q · filed 2019-08-05 | $109.52M derived: sum of 3 quarters · filed 2019-08-05 | |||||
| 2018-03-31 | $47.05M 10-Q · filed 2019-05-09 | $50.25M derived: sum of 2 quarters · filed 2019-05-09 | ||||||
| 2017-12-31 | $3.20M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-26 | $3.20M 10-K · filed 2019-03-26 | ||||||
| 2017-09-30 | $0.00 10-Q · filed 2018-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |